10-Q: CNBX Pharmaceuticals Faces Severe Financial Headwinds with Zero Revenue and Going Concern Warning

CNBX Pharmaceuticals Inc. reported no revenue and a critically low cash position in its latest 10-Q filing, raising substantial doubt about its ability to continue as a going concern amidst a significant reduction in operational activities.

Summary

• CNBX Pharmaceuticals Inc. reported no revenues for the nine months ended May 31, 2025, a significant decrease from $130,074 in the prior year period.
• Net loss for the nine months ended May 31, 2025, was $(163,867), an improvement from $(634,614) in the same period last year, primarily due to a substantial reduction in company activities and operating expenses.
• Total operating expenses decreased to $141,960 for the nine months ended May 31, 2025, from $660,680 in the prior year, with research and development expenses dropping to $0 from $268,722.
• Cash and cash equivalents stood at $13,648 as of May 31, 2025, a decrease from $26,416 on August 31, 2024.
• The company's accumulated deficit increased to $(25,118,267) as of May 31, 2025.
• Total current liabilities increased to $2,556,020 as of May 31, 2025, from $2,511,363 on August 31, 2024, including a convertible loan of $1,340,136 and $1,174,645 due to a related party.
• The company issued 61,400,000 shares of common stock for $106,442 as a result of convertible loan exercises during the nine months ended May 31, 2025, significantly increasing shares outstanding to 92,511,352.
• Subsequent to the reporting period, on June 9, 2025, an additional 9,000,000 shares were issued for $7,017 from a convertible loan conversion.

Sentiment

Score: 1

Explanation: The company is in a highly precarious financial position, reporting zero revenue, zero R&D, critically low cash, and explicitly stating a going concern doubt with no immediate financing solutions. The reduction in activities to cut costs is a severe negative for a development-stage biopharmaceutical company.

Positives

• Net loss decreased to $(163,867) for the nine months ended May 31, 2025, from $(634,614) in the prior year, primarily due to reduced operating expenses.
• Net cash used in operating activities improved to $(142,760) for the nine months ended May 31, 2025, compared to $(196,019) in the prior year period.

Negatives

• Reported zero revenue for the nine months ended May 31, 2025, indicating a complete cessation of revenue-generating activities.
• Research and development expenses were $0 for the nine months ended May 31, 2025, which is highly concerning for a pre-clinical biopharmaceutical company.
• Cash and cash equivalents are critically low at $13,648 as of May 31, 2025, insufficient to cover projected expenses.
• The company has incurred cumulative losses of $25,118,267 since inception, raising substantial doubt about its ability to continue as a going concern.
• Significant shareholder dilution occurred due to the conversion of convertible loans, with shares outstanding increasing from 31,111,352 to 92,511,352.
• The reduction in operating expenses and net loss is explicitly attributed to a 'reduction in the company's activities,' rather than improved business performance or efficiency.
• A substantial amount of $1,174,645 is due to a related party as of May 31, 2025.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to cumulative losses and critically low cash reserves.
• Inability to generate sufficient revenues to cover operating expenses and fund future operations.
• Significant challenge in raising additional investment capital, as there is no assurance that funds will be available.
• Failure to develop and implement its business plan, particularly advancing its drug candidate RCC-33 to clinical trials, due to lack of funding and reduced activities.
• Dependence on obtaining additional capital through revenue generation, debt, or equity, with no current arrangements for external financing.
• Potential for severe negative impact on viability if unable to raise necessary funds.
• Inherent limitations in internal control systems, which may not prevent all fraud and material error.

Future Outlook

The company is a pre-clinical-stage biopharmaceutical company focused on developing RCC-33 for colorectal cancer, with aspirations to commence first-in-human Phase I/II clinical trials in 2025. Its strategy involves advancing programs through clinical studies, potentially with partners, and opportunistically adding new programs. However, the company anticipates incurring a minimum of $1,000,000 in expenses over the next twelve months and explicitly states the need to raise additional funds, with no assurance of availability and no current arrangements for financing, which could severely impact its viability.

Management Comments

• "We are a pre-clinical-stage, platform technology biopharmaceutical company which has developed proprietary innovative medicines in areas of significant unmet medical needs in oncology, with a current focus on colorectal cancer ('CRC')."
• "Our drug candidate under development for colon cancer is RCC-33, a first-in-class therapy being developed primarily in two settings: one to reduce tumor cell activity in colon cancer patients as a standalone in neoadjuvant treatment or 'window of opportunity' at the time after colonoscopy, prior to cancer staging; and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy."
• "The Company hopes to start first in human Phase I/II clinical trials in 2025."
• "Our business strategy is to advance our programs through clinical studies including with partners, and to opportunistically add programs in areas of high unmet medical needs through acquisition, collaboration, or internal development."
• "The decrease [in expenses] is due to a reduction in the company's activities."
• "We expect to incur a minimum of $1,000,000 in expenses during the next twelve months of operations."
• "We will have to raise funds to pay for our expenses. We may have to borrow money from shareholders, issue equity or enter into a strategic arrangement with a third party."
• "There can be no assurance that additional capital will be available to us."
• "We currently have no arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources."
• "Since we have no such arrangements or plans currently in effect, our inability to raise funds for our operations will have a severe negative impact on our ability to remain a viable company."

Industry Context

CNBX Pharmaceuticals operates in the highly capital-intensive and risk-prone biopharmaceutical industry, specifically focusing on oncology with a pre-clinical stage drug candidate (RCC-33) for colorectal cancer. The industry typically requires significant and sustained investment in research and development, clinical trials, and regulatory approvals. The company's current state of zero revenue and zero R&D expenditure, coupled with a stated reduction in activities, suggests a significant struggle to progress its core business in line with typical industry development timelines and funding requirements. This contrasts sharply with well-funded peers who are actively advancing clinical pipelines.

Comparison to Industry Standards

• The company's zero revenue and zero research and development expenses for the nine months ended May 31, 2025, fall significantly below industry standards for a biopharmaceutical company, which typically requires substantial R&D investment to advance drug candidates through pre-clinical and clinical stages.
• The stated 'reduction in the company's activities' as a reason for decreased expenses is a concerning indicator, contrasting with the continuous and aggressive development efforts seen in successful oncology drug developers like Merck & Co. (MRK) or Bristol Myers Squibb (BMY) in their early-stage pipelines, which maintain high R&D spending.
• The company's cash position of $13,648 is extremely low for a biopharmaceutical company, especially one hoping to initiate Phase I/II clinical trials in 2025, which are notoriously expensive. For comparison, even small biotech firms often maintain cash reserves in the millions to tens of millions of dollars to fund ongoing research and prepare for clinical milestones.
• The heavy reliance on convertible loans and subsequent share dilution (over 200% increase in shares outstanding) to fund operations is a common characteristic of distressed micro-cap biotechs, unlike more established or well-funded companies that can access less dilutive financing or generate revenue.
• The explicit 'going concern' warning and lack of current financing arrangements place CNBX Pharmaceuticals far below the financial stability and operational capacity of most publicly traded biopharmaceutical companies, regardless of their stage of development.

Corporate Governance

Related Party Transactions

• Paid $37,087 in salaries, including social benefits, to two directors (Gabriel Yariv and Eyal Barad) for the nine months ended May 31, 2025, compared to $73,732 for the same period in 2024.
• Accrued $0 in salaries, including social benefits, to two directors for the nine months ended May 31, 2025, compared to $242,500 for the same period in 2024.
• As of May 31, 2025, a balance of $932,771 was outstanding payable to two directors: Gabriel Yariv and Eyal Barad.
• As of May 31, 2025, a balance of $223,645 was outstanding payable to Cannabics, Inc. (due on demand, no interest).

Stakeholder Impact

• **Shareholders:** Significant dilution has occurred due to convertible loan conversions (shares outstanding increased from 31.1M to 92.5M). The going concern warning and lack of clear financing path pose a high risk of further dilution or potential loss of investment.
• **Employees:** The reduction in company activities and zero R&D spending may indicate reduced operational scope or potential workforce adjustments, impacting job security and morale.
• **Creditors:** Convertible loan holders and related parties are exposed to significant risk given the company's going concern status and limited cash, although forbearance agreements have been noted for some creditors.
• **Customers/Partners:** As a pre-clinical stage company with no revenue, there are no direct customer impacts. Potential partners for clinical studies may be deterred by the company's financial instability and lack of R&D investment.

Next Steps

• Initiate first in human Phase I/II clinical trials for RCC-33 in 2025.
• Advance programs through clinical studies, potentially with partners.
• Opportunistically add programs in areas of high unmet medical needs through acquisition, collaboration, or internal development.
• Raise additional funds to cover a minimum of $1,000,000 in projected expenses for the next twelve months.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Oncology, Colorectal Cancer, RCC-33, Pre-clinical stage, SEC Filing, 10-Q, Financials, Going Concern, Capital Raise, Convertible Notes, Research and Development, Share Dilution